Vericel (VCEL) Free Cash Flow Growth (1y) (2012 - 2026)
Vericel (VCEL) Free Cash Flow Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 137.65% |
| 10 | Vericel | 2.32 Bn | 2.17 Bn | 49.27 Mn | 298.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 298.71% |
| Dec 31, 2025 | -118.21% |
| Sep 30, 2025 | 569.37% |
| Jun 30, 2025 | 163.28% |
| Mar 31, 2025 | -54.94% |
| Dec 31, 2024 | 1,000.16% |
| Sep 30, 2024 | -255.78% |
| Jun 30, 2024 | -101.76% |
| Mar 31, 2024 | -176.21% |
| Dec 31, 2023 | 1,599.18% |
| Sep 30, 2023 | 31.95% |
| Jun 30, 2023 | 36.10% |
| Mar 31, 2023 | 1,565.89% |
| Dec 31, 2022 | -102.28% |
| Sep 30, 2022 | 283.26% |
| Jun 30, 2022 | 539.02% |
| Mar 31, 2022 | -95.95% |
| Dec 31, 2021 | 56.83% |
| Sep 30, 2021 | -72.12% |
| Jun 30, 2021 | 124.01% |